ArticleFrontiers in medicine2026
Connecting systemic inflammation to prognosis in neuroendocrine neoplasms: a biomarker-based approach.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A predictive model for immunotherapy in extensive-stage small cell lung cancer based on peripheral blood.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuroendocrine neoplasms (NENs) comprise a diverse group of tumors with distinct clinical courses and prognoses. However, there remains a need to identify affordable biomarkers that can augment traditional prognostic indicators. Methods: To address this clinical need, we performed a retrospective analysis of 60 patients with NENs treated at the University Emergency Hospital of Bucharest (2016-2023). The baseline neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were derived from routine blood counts and were associated with demographic, histopathological, and mortality during follow-up. Logistic regression models assessed prognostic significance. Results: Of the 60 patients, 38.3% died during follow-up. Univariate analysis identified low lymphocyte counts, elevated platelet counts, PLR, NLR and SII as significant predictors of mortality. Building upon these findings, multivariate models revealed that advanced age, poorly differentiated NEC histology, and elevated SII were significantly associated with increased mortality. Conclusion: In summary, this study identifies SII, NLR and PLR as accessible, reliable, and cost-effective biomarkers with prognostic value in NENs. Thus, integrating these indices with established clinicopathological features may improve risk stratification and inform personalized management. Nonetheless, validation in larger, prospective cohorts is necessary to substantiate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.